Pharmacokinetics of Oltipraz and Its Major Metabolite (RM) in Patients With Liver Fibrosis or Cirrhosis: Relationship With Suppression of Circulating TGF-beta 1
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, S. G. | - |
dc.contributor.author | Kim, Y. M. | - |
dc.contributor.author | Choi, Y. H. | - |
dc.contributor.author | Lee, M. G. | - |
dc.contributor.author | Choi, J. Y. | - |
dc.contributor.author | Han, J. Y. | - |
dc.contributor.author | Cho, S. H. | - |
dc.contributor.author | Jang, J. W. | - |
dc.contributor.author | Um, S. H. | - |
dc.contributor.author | Chon, C. Y. | - |
dc.contributor.author | Lee, D. H. | - |
dc.contributor.author | Jang, J. J. | - |
dc.contributor.author | Yu, E. S. | - |
dc.contributor.author | Lee, Y. S. | - |
dc.date.accessioned | 2021-06-23T12:41:48Z | - |
dc.date.available | 2021-06-23T12:41:48Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2010-09 | - |
dc.identifier.issn | 0009-9236 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/39571 | - |
dc.description.abstract | Oltipraz is a potential candidate drug for the treatment of liver fibrosis (LF) and liver cirrhosis (LC). The pharmacokinetics of oltipraz and its major rearranged metabolite (7-methyl-6,8-bis(methylthio) H-pyrrolo[1,2-a]pyrazine (RM)) were evaluated after single-dose (30-90 mg) and multiple-dose (60 mg b.i.d. or 90 mg q.d. for 24 weeks) oral administration of oltipraz to patients with LF or LC. Oltipraz was safe and well tolerated in both studies. In the single-dose study, the area under the plasma concentration-time curve (AUC), peak plasma concentration (C-max), and terminal half-life (t(1/2)) of oltipraz as well as the AUC of its RM were dose dependent. Oltipraz was rapidly absorbed; the time to reach C-max (T-max) was 2-4 h. The conversion of oltipraz to RM was also rapid and substantial (AUC of RM from time 0 to the last measured concentration (AUC(last,RM))/AUC(last,oltipraz') 42-61%). In the multiple-dose study, the level of transforming growth factor-beta 1 (TGF-beta 1) (a blood fibrosis marker) was suppressed at steady-state plasma concentrations of similar to 20-60 ng/ml of oltipraz or of similar to 60-140 ng/ml of oltipraz plus RM. Overall, the pharmacokinetics, safety, and efficacy of oltipraz suggest that it may be helpful in the treatment of patients with LF or LC, at an optimal dosing regimen. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Pharmacokinetics of Oltipraz and Its Major Metabolite (RM) in Patients With Liver Fibrosis or Cirrhosis: Relationship With Suppression of Circulating TGF-beta 1 | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Y. M. | - |
dc.identifier.doi | 10.1038/clpt.2010.89 | - |
dc.identifier.scopusid | 2-s2.0-77955920049 | - |
dc.identifier.wosid | 000281288600022 | - |
dc.identifier.bibliographicCitation | CLINICAL PHARMACOLOGY & THERAPEUTICS, v.88, no.3, pp.360 - 368 | - |
dc.relation.isPartOf | CLINICAL PHARMACOLOGY & THERAPEUTICS | - |
dc.citation.title | CLINICAL PHARMACOLOGY & THERAPEUTICS | - |
dc.citation.volume | 88 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 360 | - |
dc.citation.endPage | 368 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | S6 KINASE-1 PATHWAY | - |
dc.subject.keywordPlus | REPUBLIC-OF-CHINA | - |
dc.subject.keywordPlus | CHEMOPREVENTIVE AGENT | - |
dc.subject.keywordPlus | TRANSFORMING GROWTH-FACTOR-BETA-1 | - |
dc.subject.keywordPlus | OXIDIZED METABOLITES | - |
dc.subject.keywordPlus | GENE INDUCTION | - |
dc.subject.keywordPlus | RATS | - |
dc.subject.keywordPlus | DIMETHYLNITROSAMINE | - |
dc.subject.keywordPlus | BETA | - |
dc.subject.keywordPlus | DITHIOLETHIONES | - |
dc.subject.keywordAuthor | OXIDIZED METABOLITES | - |
dc.subject.keywordAuthor | S6 KINASE-1 PATHWAY | - |
dc.subject.keywordAuthor | GENE INDUCTION | - |
dc.subject.keywordAuthor | TRANSFORMING GROWTH-FACTOR-BETA-1 | - |
dc.subject.keywordAuthor | RATS | - |
dc.subject.keywordAuthor | CHEMOPREVENTIVE AGENT | - |
dc.subject.keywordAuthor | REPUBLIC-OF-CHINA | - |
dc.subject.keywordAuthor | DIMETHYLNITROSAMINE | - |
dc.subject.keywordAuthor | DITHIOLETHIONES | - |
dc.subject.keywordAuthor | BETA | - |
dc.identifier.url | https://ascpt.onlinelibrary.wiley.com/doi/full/10.1038/clpt.2010.89 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.